These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 5051364)

  • 1. Lack of beneficial response of serum GH in acromegalic patients treated with medroxyprogesterone acetate (MPA).
    Jackson IM; Ormston BJ
    J Clin Endocrinol Metab; 1972 Sep; 35(3):413-5. PubMed ID: 5051364
    [No Abstract]   [Full Text] [Related]  

  • 2. Variable response of plasma GH in acromegalic patients treated with medroxyprogesterone acetate.
    Malarkey WB; Daughaday WH
    J Clin Endocrinol Metab; 1971 Sep; 33(3):424-31. PubMed ID: 4936883
    [No Abstract]   [Full Text] [Related]  

  • 3. Unsuccessful treatment of acromegaly with medroxyprogesterone acetate.
    Atkinson RL; Dimond RC; Howard WJ; Earll JM
    Acta Endocrinol (Copenh); 1974 Sep; 77(1):19-25. PubMed ID: 4408390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of medroxyprogesterone acetate (MPA) on the blood level of STH in 12 patients with acromegaly].
    Liuzzi A; Chiodini PG; Botalla L; Silvestrini F
    Ann Endocrinol (Paris); 1972; 33(4):426-30. PubMed ID: 4664003
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of medroxyprogesterone acetate therapy on carbohydrate metabolism in acromegaly.
    Blum I; Karp M; Laron Z
    Isr J Med Sci; 1972 Jun; 8(6):881-2. PubMed ID: 5051830
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term administration of medroxyprogesterone acetate (MPA) to acromegalic patients.
    Josefsberg Z; Laron Z; Mathias S; Keret R
    Clin Endocrinol (Oxf); 1974 Apr; 3(2):195-202. PubMed ID: 4837878
    [No Abstract]   [Full Text] [Related]  

  • 7. A trial of medroxyprogesterone acetate in acromegaly.
    Rake JS; Hafiz SA; Lessof MH; Snodgrass GJ
    Clin Endocrinol (Oxf); 1972 Apr; 1(2):181-7. PubMed ID: 4664381
    [No Abstract]   [Full Text] [Related]  

  • 8. Acromegaly treated with chlorpromazine. A case study.
    Kolodny HD; Sherman L; Singh A; Kim S; Benjamin F
    N Engl J Med; 1971 Apr; 284(15):819-22. PubMed ID: 5549804
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of medroxyprogesterone on plasma somatotropin (GH) levels in 14 patients with acromegaly].
    Tourniaire J; Pousset G
    Ann Endocrinol (Paris); 1973; 34(2):222-4. PubMed ID: 4745280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.
    Demura R; Yamaguchi H; Demura H; Shizume K
    Endocrinol Jpn; 1978 Aug; 25(4):355-9. PubMed ID: 710371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
    Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
    Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorpromazine treatment and growth hormone secretory responses in acromegaly.
    Dimond RC; Bramer SR; Atkinson RL; Howard WJ; Earll JM
    J Clin Endocrinol Metab; 1973 Jun; 36(6):1189-95. PubMed ID: 4706207
    [No Abstract]   [Full Text] [Related]  

  • 14. Grwoth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate.
    Concannon P; Altszuler N; Hampshire J; Butler WR; Hansel W
    Endocrinology; 1980 Apr; 106(4):1173-7. PubMed ID: 6444575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary studies of plasma growth hormone releasing activity during medical therapy of acromegaly.
    Hagen TC; Lawrence AM; Kirsteins L
    Horm Metab Res; 1978 Jul; 10(4):310-3. PubMed ID: 98420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate (Provera R ) therapy in acromegaly associated with heart disease.
    Wallach HW; Shapiro JR; Mendelson SH
    Med Ann Dist Columbia; 1973 Jan; 42(1):17-22. PubMed ID: 4511103
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of plasma somatotropin levels in acromegaly treated with medroxyprogesterone acetate].
    Strauch G; Bricaire H
    Ann Endocrinol (Paris); 1973; 34(2):228-31. PubMed ID: 4745282
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.